Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics (Nasdaq: TXG) has launched Xenium Protein, an innovative addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell and tissue section in a single automated run. This breakthrough represents the first fully integrated spatial multiomic workflow for the Xenium platform.
The new product features ready-to-use protein subpanels that work alongside RNA panels, including dozens of proteins involved in cell growth, signaling, and immune response. The technology streamlines research workflows by eliminating the need for separate technologies or sample sections, particularly beneficial for studying cancer, immunology, and complex diseases.
Early adoption by companies like Sanofi demonstrates the platform's value in providing comprehensive tissue architecture analysis and cell-cell interaction insights without complex data co-registration requirements.
10x Genomics (NASDAQ: TXG) reported Q2 2025 financial results with total revenue of $172.9 million, including a $27.3 million patent litigation settlement. Excluding the settlement, revenue was $145.6 million, representing a 5% year-over-year decrease.
Key highlights include a $30 million acquisition of Scale Biosciences, improved gross margin of 72% (67% excluding license revenue), and net income of $34.5 million compared to a loss in the previous year. The company maintains a strong cash position of $447.3 million.
For Q3 2025, 10x Genomics projects revenue between $140-144 million, accounting for approximately $4 million in accelerated Chinese purchases due to potential tariff changes.
10x Genomics (Nasdaq: TXG) has announced a definitive agreement to acquire Scale Biosciences, a leader in innovative single cell analysis. The acquisition aims to enhance TXG's Chromium platform by integrating Scale's combinatorial indexing and quantum barcoding technologies.
The deal brings aboard Scale's scientific founders as advisors, including prominent researchers from Stanford University and University of Washington. The acquisition will support TXG's multi-year product roadmap focused on expanding single cell analysis capabilities, making it more powerful, affordable, and accessible to researchers globally.
10x Genomics will maintain support for existing Scale customers and continue key initiatives like the 100 Million Cell Challenge and the Billion Cells Project, while keeping core Scale products available in the market.
10x Genomics (Nasdaq: TXG) and A*STAR Genome Institute of Singapore have announced the TISHUMAP research collaboration to advance drug target discovery using spatial biology and AI. The study will analyze up to 2,500 FFPE clinical tissue samples from gastric, liver, and colorectal cancers using 10x Genomics' Xenium platform.
The collaboration leverages Xenium's unique capability to visualize gene activity within intact tissue samples at the cellular level, combined with AI to identify novel biomarkers and drug targets. The partnership includes development of custom gene panels and intelligent software pipelines to manage large-scale spatial biology data, aiming to accelerate the development of new diagnostics and personalized treatment approaches for cancer and inflammatory diseases.
10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, has scheduled its Q2 2025 earnings release for August 7, 2025, after market close. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss financial results and business developments.
The earnings release will be available on the company's website before the call, and investors can access the live webcast through the investor relations section. A replay will be available for at least 45 days following the event.
10x Genomics (TXG) has reached a comprehensive settlement agreement with Bruker Corporation to resolve all worldwide patent litigation disputes. Under the settlement terms, Bruker will pay $68 million in equal quarterly installments between Q3 2025 and Q2 2026, plus ongoing royalties on spatial biology product sales throughout the licensed patents' duration. The agreement includes global patent cross-licenses and complete withdrawal of all legal proceedings in the United States, Germany, and the European Unified Patent Court.
10x Genomics (Nasdaq: TXG), a pioneer in single cell and spatial biology, has announced its upcoming participation in the BofA Securities 2025 Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, May 13, at 11:20 a.m. Pacific Time.
Investors and interested parties can access the event through a live webcast available on the company's investor relations website at investors.10xgenomics.com. For those unable to attend the live session, the webcast recording will remain accessible for a minimum of 30 days following the event.
10x Genomics (TXG), a leader in single cell and spatial biology, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call and webcast for analysts and investors at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day.
The financial results will be accessible through a news release on the company's website before the conference call. Interested parties can access the live audio webcast through the 'Investors' section at investors.10xgenomics.com, with a replay available for at least 45 days following the event.
10x Genomics (TXG) has secured a significant legal victory against Parse Biosciences through a consent agreement entered on February 25, 2025, in the U.S. District Court for the District of Delaware. Parse agreed to a worldwide permanent injunction preventing them from making, using, or selling their planned ATAC and ATAC-Multiome Single Cell products.
Parse has admitted that 10x's ATAC-seq patents are valid, enforceable, and infringed by Parse's use of ATAC-seq methods and compositions. The agreement was reached one week before the scheduled trial. While this resolves the ATAC-related dispute, litigation regarding Parse's gene expression products continues, with additional patents under appeal. The March 2025 trial for remaining patent infringement claims has been stayed pending these appeals.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
